NCOA2, nuclear receptor coactivator 2, 10499

N. diseases: 95; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.380 Biomarker disease BEFREE Further secondary and tertiary hit characterization assays are underway to select AR-TIF2 PPI inhibitor/disruptor hits suitable for medicinal chemistry lead optimization and development into novel PCa/CRPC therapeutics. 30109944 2019
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.380 Biomarker disease BEFREE Furthermore, for the first time, we detected a structural rearrangement involving NCOA2 in PCa. 26799514 2016
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.380 Biomarker disease BEFREE Concordant assessment of DNA copy number, mRNA expression, and focused exon resequencing in 218 prostate cancer tumors identified the nuclear receptor coactivator NCOA2 as an oncogene in approximately 11% of tumors. 20579941 2010
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.380 Biomarker disease BEFREE Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. 19240160 2009
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.380 AlteredExpression disease BEFREE Depletion of TIF2 reduced expression of AR-induced target genes and slowed proliferation of AR-dependent and AR-independent prostate cancer cells. 17079484 2006
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.380 AlteredExpression disease BEFREE Cofactors SRC-1, RAC3, p300/CBP, TIF-2, and Tip60 are upregulated in advanced prostate cancer. 16598769 2006
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.380 AlteredExpression disease BEFREE AR coactivators SRC-1 and TIF-2 are up-regulated in tissue specimens obtained from patients who failed prostate cancer endocrine therapy. 15663989 2004
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.380 Biomarker disease CTD_human The three coactivators, TIF-2, SRC-1 and RAC3, are up-regulated in relapsed prostate cancer. 12237244 2002
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.380 AlteredExpression disease BEFREE The three coactivators, TIF-2, SRC-1 and RAC3, are up-regulated in relapsed prostate cancer. 12237244 2002
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.360 Biomarker disease BEFREE However, the transcriptional role of SRC-2 in breast cancer is still ambiguous. 30048685 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.360 Biomarker disease BEFREE In conclusion, our results suggest NCOA2 as a potential target of therapeutics against breast cancer. 30941313 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.360 Biomarker disease BEFREE However, the transcriptional role of SRC-2 in breast cancer is still ambiguous. 30048685 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.360 Biomarker disease BEFREE In conclusion, our results suggest NCOA2 as a potential target of therapeutics against breast cancer. 30941313 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.360 AlteredExpression disease BEFREE As the members of the p160/nuclear receptor co-activator (NCOA) family, NCOA1, NCOA2 and NCOA3 are known to be overexpressed in breast cancer and essentially involved in estrogen-mediated cancer cell proliferation we asked if these proteins are involved in the ERα-mediated transactivation of PLAC1 in breast cancer cells. 24304549 2013
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.360 AlteredExpression disease BEFREE As the members of the p160/nuclear receptor co-activator (NCOA) family, NCOA1, NCOA2 and NCOA3 are known to be overexpressed in breast cancer and essentially involved in estrogen-mediated cancer cell proliferation we asked if these proteins are involved in the ERα-mediated transactivation of PLAC1 in breast cancer cells. 24304549 2013
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.360 Biomarker disease BEFREE Collectively, these data indicate that SRC control of basal and hormone-regulated proliferations is not solely mediated by ERα, and suggest that targeting growth inhibition by disrupting SRC-2 and SRC-3 function may be an effective approach to inhibit the growth of tamoxifen-resistant breast cancer. 21059860 2011
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.360 Biomarker disease BEFREE Collectively, these data indicate that SRC control of basal and hormone-regulated proliferations is not solely mediated by ERα, and suggest that targeting growth inhibition by disrupting SRC-2 and SRC-3 function may be an effective approach to inhibit the growth of tamoxifen-resistant breast cancer. 21059860 2011
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.360 Biomarker disease CTD_human Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. 20332317 2010
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.360 Biomarker disease BEFREE Genes of known importance in breast cancer and estrogen signaling, including ERBB2, PGR, MYC, CLU, and NCOA2, were among those identified as Sin3A-responsive. 20920219 2010
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.360 Biomarker disease CTD_human Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. 20332317 2010
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.360 Biomarker disease BEFREE Genes of known importance in breast cancer and estrogen signaling, including ERBB2, PGR, MYC, CLU, and NCOA2, were among those identified as Sin3A-responsive. 20920219 2010
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.360 AlteredExpression disease BEFREE Amplified in breast cancer (AIB1 or SRC-3) is an estrogen receptor coregulatory protein that together with other co-activators like transcription intermediary factor 2 (TIF2) and nuclear receptor co-repressor (NCoR), is implicated in estrogen signaling pathway and estrogen regulated tumor progression. 18521745 2009
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.360 AlteredExpression disease BEFREE Amplified in breast cancer (AIB1 or SRC-3) is an estrogen receptor coregulatory protein that together with other co-activators like transcription intermediary factor 2 (TIF2) and nuclear receptor co-repressor (NCoR), is implicated in estrogen signaling pathway and estrogen regulated tumor progression. 18521745 2009
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.320 Biomarker group BEFREE Elevated expression of steroid receptor coactivator-3 (SRC-3), a member of the p160 family of nuclear receptor coactivators, has been implicated in tamoxifen resistance of breast tumors while the involvement of the two other members of this family, SRC-1 and SRC-2, is less well characterized. 21059860 2011
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.320 Biomarker group CTD_human Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. 20332317 2010